These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2410121)

  • 1. Clinical pharmacokinetics of vindesine infusion.
    Rahmani R; Kleisbauer JP; Cano JP; Martin M; Barbet J
    Cancer Treat Rep; 1985; 69(7-8):839-44. PubMed ID: 2410121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of vindesine bolus and infusion.
    Jackson DV; Sethi VS; Long TR; Muss HB; Spurr CL
    Cancer Chemother Pharmacol; 1984; 13(2):114-9. PubMed ID: 6467494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of vindesine given as an intravenous bolus and 24-hour infusion in humans.
    Ohnuma T; Norton L; Andrejczuk A; Holland JF
    Cancer Res; 1985 Jan; 45(1):464-9. PubMed ID: 3965152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial clinical study with vindesine: tolerance to weekly iv bolus and 24-hour infusion.
    Ohnuma T; Greenspan EM; Holland JF
    Cancer Treat Rep; 1980 Jan; 64(1):25-30. PubMed ID: 6929728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Five-day continuous infusion of vindesine in the treatment of non-small cell lung cancer--clinical pharmacokinetics of vindesine].
    Saito Y; Mori K; Tominaga K; Yokoi K; Miyazawa N
    Gan To Kagaku Ryoho; 1991 Sep; 18(12):2129-32. PubMed ID: 1653559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combination chemotherapy of nicardipine and vindesine sulfate, cis-diammine dichloroplatinum (II) for patients with advanced esophageal carcinoma].
    Akazawa S; Honda T; Sampi K; Futatsuki K
    Gan To Kagaku Ryoho; 1984 Apr; 11(4):943-7. PubMed ID: 6539096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma.
    Mok TS; Kanekal S; Lin XR; Leung TW; Chan AT; Yeo W; Yu S; Chak K; Leavitt R; Johnson P
    Cancer; 2001 Jun; 91(12):2369-77. PubMed ID: 11413527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacokinetics of cisplatin and vindesine in a patient with chronic renal failure undergoing hemodialysis].
    Ayabe H; Uchikawa T; Kimino K; Tagawa Y; Kawahara K; Tomita M
    Gan To Kagaku Ryoho; 1989 Sep; 16(9):3283-5. PubMed ID: 2782920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of vindesine: repeated treatments by intravenous bolus injections.
    Rahmani R; Martin M; Favre R; Cano JP; Barbet J
    Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1409-17. PubMed ID: 6542010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
    Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG; Balcerzak SP; Kraut EH
    Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vinorelbine and 5-fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer: an analysis of results in clinical practice of the Gruppo Oncologico Italia Meridionale (GOIM).
    Gebbia V; Caruso M; Borsellino N; Ajello R; Tirrito ML; Chiarenza M; Valenza R; Verderame F; Varvara F; Marrazzo A; Bajardi E; Ferrao F; Bordonaro R; Tralongo P
    Anticancer Res; 2006; 26(4B):3143-50. PubMed ID: 16886648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of vindesine, cisplatin, and hexamethylmelamine (VCH) in small cell carcinoma of the lung.
    Daugaard G; Hansen HH; Rørth M
    Cancer Treat Rep; 1984 Sep; 68(9):1179-81. PubMed ID: 6090016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.
    Bhalla KN; Kumar GN; Walle UK; Ibrado AM; Javed T; Stuart RK; Reed C; Arbuck SG; Walle T
    Clin Cancer Res; 1999 Jul; 5(7):1723-30. PubMed ID: 10430075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
    Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
    Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion.
    Yap HY; Blumenschein GR; Bodey GP; Hortobagyi GN; Buzdar AU; DiStefano A
    Cancer Treat Rep; 1981; 65(9-10):775-9. PubMed ID: 7273012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
    Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG
    Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative study on quality of life between weekly and monthly chemotherapy with cisplatin, vindesine and mitomycin C in patients with non-small cell lung cancer].
    Ishihara Y; Ichiwata T; Kuramitsu K; Yoneda S; Yamamoto M; Takizawa T; Ogata T; Uchiyama T; Yoshida K
    Gan To Kagaku Ryoho; 1998 Jun; 25(7):1013-20. PubMed ID: 9644316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.